Format

Send to

Choose Destination
JAMA. 2016 Nov 15;316(19):1997-2007. doi: 10.1001/jama.2016.15450.

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.

Author information

1
University of California, San Francisco.
2
Group Health Research Institute, Seattle, Washington.
3
University of Iowa, Iowa City.
4
Columbia University, New York, New York.
5
State University of New York Upstate Medical University, Syracuse.
6
Pima County Department of Health, Tucson, Arizona.
7
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts8Now with the National Institutes of Health, Bethesda, Maryland (was not affiliated with the National Institutes of Health while a member of the USPSTF).
8
Duke University, Durham, North Carolina.
9
Fairfax Family Practice Residency, Fairfax, Virginia11Virginia Commonwealth University, Richmond.
10
Yale University, New Haven, Connecticut.
11
University of Alabama at Birmingham.
12
University of Missouri, Columbia.
13
University of California, Los Angeles.
14
University of Washington, Seattle.
15
Stanford University, Stanford, California.
16
Brown University, Providence, Rhode Island.
17
University of Texas at Austin.

Abstract

Importance:

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.

Objective:

To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.

Evidence Review:

The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.

Conclusions and Recommendations:

The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).

PMID:
27838723
DOI:
10.1001/jama.2016.15450
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center